Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Ibopamine→

Ibopamine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
66195-31-1
Molecular formula
C17H25NO4
Molecular weight
307.4 g/mol
Drug class
Oral dopamine agonist prodrugdopaminergic and adrenergic vasodilator
Mechanism of action
Hydrolysed by esterases to epinine (N-methyldopamine), which activates D1 and D2 dopaminergic receptors and, to a lesser extent, alpha- and beta-adrenergic receptors. The resulting haemodynamic actions include vasodilation and changes in cardiac loading conditions.
Indications / reported uses
  • Historically investigated and used in some countries for congestive heart failure; it is not a standard contemporary heart-failure therapy and current marketing authorisation should be checked locally.

Sources: https://pubmed.ncbi.nlm.nih.gov/1675550/ · https://pubmed.ncbi.nlm.nih.gov/7906158/ · https://pubmed.ncbi.nlm.nih.gov/7743694/

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Ibopamine Environmental Risk Assessment (ERA) (the Ibopamine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.